Kite, a division of Gilead Sciences (NASDAQ:GILD), and Arcellx (NASDAQ:ACLX) will begin a phase 3 study of their CAR-T multiple myeloma treatment anitocabtagene autoleucel (anito-cel) in the H2 2024 ...
Source LinkKite, a division of Gilead Sciences (NASDAQ:GILD), and Arcellx (NASDAQ:ACLX) will begin a phase 3 study of their CAR-T multiple myeloma treatment anitocabtagene autoleucel (anito-cel) in the H2 2024 ...
Source Link
Comments